Compare HUIZ & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HUIZ | INAB |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.8M | 13.7M |
| IPO Year | 2019 | 2020 |
| Metric | HUIZ | INAB |
|---|---|---|
| Price | $1.30 | $1.39 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $2.30 | ★ $6.00 |
| AVG Volume (30 Days) | 11.5K | ★ 34.4K |
| Earning Date | 06-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.58 | N/A |
| Revenue Next Year | $6.64 | N/A |
| P/E Ratio | $7.81 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.04 | $1.17 |
| 52 Week High | $4.16 | $2.73 |
| Indicator | HUIZ | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 53.23 | 39.97 |
| Support Level | $1.19 | $1.33 |
| Resistance Level | $1.55 | $1.53 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 87.97 | 27.99 |
Huize Holding Ltd is an independent online insurance product and service platform in China. The company distributes on its platform insurance products underwritten by the insurance companies that cooperate with the company, which the company refers to as its insurer partners, and helps them reach a large number of insurance clients. The company's platform offers a digitalized insurance purchase experience and services through various internet and mobile internet channels. The company generates revenues from the insurance brokerage fees paid by its insurer partners.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.